Q-omics provides the consensus-scored PRB4 profile across patient tissues and cancer cell-line models. PRB4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRB4 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PRB4 RNA expression shows 7,151 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUAD, HNSC, and LAML as cancer lineages where PRB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRB4 survival associations across molecular data types. PRB4 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRB4 RNA expression–survival associations across cancer types. High PRB4 expression shows unfavorable associations in LUAD, THCA, MESO, ACC and STAD, but favorable associations in THYM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PRB4 RNA expression.
This table summarizes PRB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRB4 shows lower tumor expression in HNSC and higher tumor expression in BRCA, LUAD and KICH. The HNSC box plot shows higher PRB4 RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p = .002).
This table shows molecular features associated with PRB4 in patient tissues and cancer cell lines. In patient samples, PRB4 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, PRB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
